Article Text

Download PDFPDF
Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers
  1. Yong Poovorawana,
  2. Suvimol Sanpavatb,
  3. Saowani Chumdermpadetsukb,
  4. Assad Safaryc
  1. aViral Hepatitis Research Unit Chulalongkorn University Hospital, Bangkok, Thailand, bDepartment of Paediatrics, cSmithKline Beecham Biologicals, Rixensart, Belgium
  1. Dr Y Poovorawan, Viral Hepatitis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.


Neonates of hepatitis B surface antigen (HBsAg) positive and hepatitis B encoded antigen (HBeAg) positive mothers received 10 μg of recombinant hepatitis B vaccine at months 0, 1, 6, or 0, 1, 2, 12, with or without immunoglobulin at birth, and were followed up to the age of 8 years for HBsAg, anti-HBc, and anti-HBs. Some were boosted at month 60. The overall vaccine protection at month 12 was 96.2%. No child became a chronic carrier beyond the age of 3 years, showing that this vaccine provides immediate protection against HBsAg carriage, and long term protection against fetally acquired HBsAg. After month 60 hepatitis B serological markers without disease, indicating re-exposure to HBV, reappeared in comparable numbers among boosted and non-boosted children (5 for a total of 167 children).

 This vaccine provides long term protection against hepatitis B chronic carriage and infection in high risk neonates with or without a month 60 booster. A booster at the age of 5-6 years or 11–12 years would reduce HBV infection, viral circulation and transmission, while ensuring long term antibody persistence.

  • hepatitis B vaccine
  • transmission
  • boosters
  • long term efficacy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.